Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
September 16, 2025

Establishing the clinical IDS pharmacist role in a phase 1 clinic.

View Full Paper
Ask AI
Bookmark
Share

Authors

FEF. EstrellaUniversity of the West of EnglandJLJ. LewinCape Town HVTN Immunology Laboratory / Hutchinson Centre Research Institute of South AfricaASA. SchuesslerCape Town HVTN Immunology Laboratory / Hutchinson Centre Research Institute of South Africa

Discussion

Loading...

Member takes

Implication

Retrospective review highlights the role of clinical pharmacists in medication management and trial safety.

Key Points

  • Integration of clinical IDS pharmacists improved medication management in phase 1 oncology trials, enhancing patient safety.
  • During the pilot phase, pharmacists documented 311 interventions, mainly in concomitant medication reviews and drug information.
  • Observational analysis comparing pilot and follow-up periods showed over 85% of inquiries came from study coordinators and nurses.
  • Results indicate a need for expanding pharmacist roles in clinical trials to adapt to increasing complexities.

Cite This Study

Estrella et al. (2025) studied this question.

synapsesocial.com/papers/68c93fe601120bef803baeb2https://doi.org/10.1177/10781552251376302
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 3 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1Approaches to Phase 1 Clinical Trial Design Focused on Safety, Efficiency, and Selected Patient Populations: A Report from the Clinical Trial Design Task Force of the National Cancer Institute Investigational Drug Steering Committee2010 · 202 citations
  2. 2Improving the impact of pharmacy interventions in hospitals2023 · 9 citations
  3. 3Potential cytochrome P-450 drug–drug interactions in adults with metastatic solid tumors and effect on eligibility for Phase I clinical trials2015 · 17 citations